Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Climb Bio Inc (CLYM) Market Cap & Valuation Ratios

Climb Bio Inc (CLYM) has a market cap of $585.3M, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CLYMClimb Bio IncFollow CLYM — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
585.3M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
11 Nov, in 18 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
CLYM0.6———-9.3%——-36%
WVE0.6—4.0——-30%-333%-255%
CADL0.6———-9.3%———
CRMD0.63.81.12.0—+281%47%57%
SGMT0.6———-7.0%——-59%
IMMX0.6———-6.7%———
ZVRA0.610.72.74.35.6%+119%61%68%
DBVT0.6—80.2——+29%——
MDXG0.697.81.35.77.8%-2%2%4%
OLMA0.6——————-65%
ACRS0.6—56.0—-11.3%-51%—-82%
Median of these 1010.73.34.3-6.9%+13%25%-59%

.

Growth vs. price

each dot a company · hover or tap for values
51020501000%+25%+50%+75%+100%+125%+150%+175%+200%+225%+250%+275%revenue growth, TTM →P/E (log)CRMDZVRAMDXG

CLYM and WVE and CADL and SGMT and IMMX and DBVT and OLMA and ACRS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.

Climb Bio Inc — questions

What is Climb Bio Inc's market cap?
$585.3M.

Every figure on this page comes from Climb Bio Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.